Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)

About this Study

The purpose of this study screening step is to perform tests on genes and proteins produced by genes in tumor samples for certain features that investigational targeted agents used in this study are specifically designed to work against.  Then the purpose is to assign a treatment sub-study that is chosen based on the results (genes and proteins called "biomarkers") of this genetic testing on your tumor sample.  The purpose of the treatment part of this study is to compare the effects, good and bad, of these investigational agents to the usual approach to treating your type of cancer.

Sponsor Protocol ID:S1400
IRB Number:2015-0234
Actively Enrolling
Interventional
Phase 2
May 29, 2019
Eligibility Criteria
Both Male and Female
Yes
No
No

Inclusion CriteriaThis study was designed to include women and minorities, but was not designed to measure differences of intervention effects. Accrual is expected to reach between 500 and 800 patients per year.

Exclusion CriteriaNone

Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute
University Hospital
Contact Information
Contact Name: Sandra Powe
Phone Number: 601-984-1965
Email: spowe@umc.edu
Principal Investigator:Wilkinson, Kelly J, M.D.
How to participate in our Clinical Trials